I’ve written many times about Nutrition and NETs – clearly it should say NENs (Neuroendocrine Neoplasms) as the issues also extend to Neuroendocrine Carcinomas. I was helped in the early days by my friend and ‘nutrition for NET’ mentor Tara Whyand, at the time, probably the top NET Nutrition Registered Dietitian in the world. Perhaps she still is.
Much of what Tara said and wrote, and what I emphasised, particularly in my blog and my patient group, was that much of this was not fully integrated into NEN patient care as part of a multi disciplinary approach. Many attempts have been made, a good example is the inclusion of dietary support in ENETS centres of excellence and the inclusion of dietitians on MDT/Tumour Board meetings. But it’s true to say there is no standard for such arrangements.
I was therefore delighted to see this ENETS position statement on nutritional support in Neuroendocrine Neoplasms (NENs) which may lead to more standardisation and increased support for these matters – the authors headed up the statement with the words “Controversies in NEN” which is probably still accurate in 2025 despite some of the science and statistics being around for double figure years.
List of specific questions on nutritional support in NEN used in the manuscript.
Question 1. What is the prevalence of malnutrition in NEN?
Question 2. What are the main reasons for under-nutrition?
Question 3. Are there specific micronutrient deficiencies in NEN?
Question 4. Which and when nutrition assessment is required in NEN?
Question 5. How do we personalize nutrition in NEN patients?
Question 6. How do we address obesity in NEN?
Question 7. How to promote research in Nutrition in NEN?
Interested? See link below:
Grozinsky-Glasberg S, Hofland J, Alband S, et al. Controversies in NEN: An ENETS Position Statement on nutritional support in neuroendocrine neoplasms. J Neuroendocrinol. 2025;e70062. doi:10.1111/jne.70062
Click here to read.
Author’s Summary
I think the heading of this section remains accurate. NENs are known to be a highly heterogenous collection of cancers and this extends to issues such as nutrition. You may be interested in also checking out all my previous nutrition articles taken from esteemed sources and written by myself as a patient who has experienced many of these issues (a lot of the work was quoted from Tara Whyand mentioned above). She now works as a private dietitian and I recommend her if you have access.
Click here or on the picture above to read more.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Click here and answer all questions to join my private Facebook group
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol)
Vitamin D deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) — but that does not automatically mean your deficiency is caused by your NET. Vitamin D deficiency is widespread in the general population, particularly in northern latitudes, older adults, and people with limited sun exposure. However, NET patients accumulate multiple, well‑recognised risk factors,… Read more: Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol) - Cancer: Words are important but so is context
Words are very important to cancer patients, some people hang their hats on them and put their feet up, and some people google them until they are tied in a knot, still fraught with worry. Why can’t doctors just tell me in layman’s language? Easy answer ……. because it is not an exact science. Doctors… Read more: Cancer: Words are important but so is context - Newsletter covering January and February 2026
Overview Many thanks for the support in January and February 2026. This is a double month newsletter due to my 27 day holiday! 2026 Blog Activity for January and February Actually, despite my holiday figures are pretty much normal. I had a great month in December 2025, perhaps I was overperforming as I was anticipating… Read more: Newsletter covering January and February 2026 - Neuroendocrine Tumours (NET) – Vitamin B12 (Cobalamin)
Vitamin B12 deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) – what that means is there is a chance your deficiency as a NET patients may not be related to your NET. However, it’s a fairly common comorbidity reported in NET patients and it’s important to note the mechanisms differ by primary… Read more: Neuroendocrine Tumours (NET) – Vitamin B12 (Cobalamin) - Sometimes you gotta climb that bridge!
When I was a young lad, I didn’t seem to have a fear of heights, not that I got many chances to test it but a couple of things springs to mind. As a ‘feral youth’ I once climbed to the top of a factory building without fear. I won’t divulge any further detail, just… Read more: Sometimes you gotta climb that bridge! - 50 years of marriage – in sickness and in health
When I was diagnosed with metastatic Neuroendocrine Cancer in 2010, there’s a lot of milestones I doubted I would reach. One is today and I can now tick off another and be thankful for reaching it. I have been married to a kind and beautiful lady for 50 years on – 29th March 2025. I’ve… Read more: 50 years of marriage – in sickness and in health - Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. Zanzalintinib (XL092) is an investigational,… Read more: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311) - Next Generation Total-Body PET/CT: Challenges and Opportunities
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide more detailed imaging and acquire PET images in a single bed position. Indeed, vertex to thigh imaging for oncological indications can be obtained in most of the population with the… Read more: Next Generation Total-Body PET/CT: Challenges and Opportunities - Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the news – click here Clinical Trial Document – click here Limited to US (6 locations) (so far). CRN09682, a first‑in‑class non‑peptide drug conjugate (NDC) developed by Crinetics Pharmaceuticals. The company… Read more: Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - Ronny Allan – a review of my blog activity December 2025
Here is the monthly summary of December 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis, discovery of the best doctors and treatments. December is normally a quiet month, often the quietist month of the year. However, this year, it was the best figures for the whole of 2025. … Read more: Ronny Allan – a review of my blog activity December 2025 - A review of 2025 on RonnyAllan.NET
Summary of 2025 from Ronny It was a good year for my advocacy work but a difficult year personally which had some impact on my advocacy work. I had to spend quite a bit of time looking after my brother’s affairs when he was diagnosed with dementia and is now living in residential care. That… Read more: A review of 2025 on RonnyAllan.NET - 15 years of Christmas!
15 Christmas celebrations since diagnosis. A thankful statement My Facebook memories today are full of Christmas activities including my first Christmas following diagnosis of advanced Neuroendocrine Cancer. I had been out of hospital for only 4 weeks following major surgery in 2010. I remember the whole of my own family attended, my son and daughter’s… Read more: 15 years of Christmas! - Another Next Generation PET/CT is coming soon. The Omni 128cm Total Body PET – Small Australian trial at Peter Mac
A Global first for NET. Omni 128cm Total Body PET at the Peter MacCallum Cancer Centre in Melbourne Australia. According to Professor Michael Hofman, they have been using the camera for a couple weeks and it is exceeding their expectations. They’re running a short trial comparing results against regular PETs. The great news is that… Read more: Another Next Generation PET/CT is coming soon. The Omni 128cm Total Body PET – Small Australian trial at Peter Mac - Neuroendocrine Cancer: I hadn’t heard of it until I was diagnosed with it
My diagnosis came with many strange words including, “carcinoid” and “neuroendocrine” ……… can you spell that please, I said to the doctor. I had a low ki67 figure from a tissue sample taken percutaneously from my liver, it seemed pretty good that I was only 5 in a range of 0-100 but somehow the word… Read more: Neuroendocrine Cancer: I hadn’t heard of it until I was diagnosed with it - Ronny Allan’s ‘PoNETry’ © – An Ode to Invisible Illness
Ronny Allan’s ‘PoNETry’ © series can be shared with poetry credit to: RonnyAllan.NET Thanks for reading Ronny I also have one about Lanreotide (or “butt darts” in general) – click here Click here and answer all questions to join my private Facebook group Thanks for reading. Ronny Blog Facebook. Like this page please. Personal Facebook.… Read more: Ronny Allan’s ‘PoNETry’ © – An Ode to Invisible Illness
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.
